ACUR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACUR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Acura Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2021 was $-0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Acura Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Acura Pharmaceuticals (OTCPK:ACUR) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of Acura Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Bruce F Wesson | director | 1827 PACIFIC ST BROOKLYN NY 11233 |
William G Skelly | director | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 |
George K Ross | director | 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596 |
James F Emigh | officer: VP, Corporate Development | |
Immanuel Thangaraj | director | 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380 |
Robert A Seiser | officer: VP, Treasurer & Controller | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067 |
Robert B Jones | officer: President & CEO | C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067 |
Albert W Brzeczko | officer: VP Pharmaceutical Sciences APT | C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067 |
Peter A Clemens | officer: Senior VP & CFO | C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233 |
Abuse Deterrent Pharma, Llc | 10 percent owner | 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202 |
Claudius Llc | 10 percent owner | C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
John Schutte | 10 percent owner | 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233 |
Galen Partners Iii L P | 10 percent owner | 610 FIFTH AVE 5TH FL NEW YORK NY 10020 |
Galen Management, Llc | 10 percent owner | 680 WASHINGTON BLVD, STAMFORD CT 06901 |
Galen Employee Fund Iii Lp | 10 percent owner | 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
From GuruFocus
By Marketwired Marketwired • 07-26-2021
By Marketwired Marketwired • 10-29-2020
By Marketwired Marketwired • 10-10-2018
By GuruFocusNews GuruFocusNews • 03-01-2022
By Marketwired Marketwired • 11-28-2018
By Marketwired Marketwired • 02-28-2020
By GuruFocusNews GuruFocusNews • 02-14-2022
By Marketwired Marketwired • 06-14-2021
By Marketwired Marketwired • 05-17-2021
By gurufocus 10qk • 07-29-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.